Trial Profile
3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow: A Phase II Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Granulocyte macrophage colony stimulating factor (Primary) ; Isotretinoin (Primary) ; Monoclonal antibody 3F8 (Primary)
- Indications Cancer metastases; Neuroblastoma
- Focus Therapeutic Use
- 24 Jul 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 04 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.